Jan Schakowsky

Pocan, Warren Lead Lawmakers in Renewed Push to Stop Private Equity Looting

Senator Baldwin Leads Bill to Crack Down on Big Corporations Price Gouging Americans

Rep. Pocan Condemns Hamas Attacks, Urges Protection of Innocent Civilians

Schakowsky, Pocan, Jayapal, McGovern Lead 55 Members in Letter Condemning Hamas Attacks, Urging Protection of Innocent Civilian Lives

Congresswoman Gwen Moore and Congresswoman Jan Schakowsky Introduce the COLAs Don’t Count Act

Senator Baldwin Leads 117 Members of Congress in Asking the Biden Administration to Request Budget Funding that Adequately Reflects the President’s Priority to Advance LGBTQI+ Rights Around the World

Baldwin, Warren, Schakowsky Introduce Bicameral Legislation to Crack Down on Corporate Price Gouging

This bill comes as opportunistic corporations are using inflation as cover to abuse their pricing power and jack up prices for American consumers

Senator Baldwin Supports Legislation to Give Every American Lifesaving N95 Masks

More than 50 Democratic Colleagues Sponsor the Masks for All Act in the House and Senate

Pocan, Sánchez Introduce Bill to Strengthen Social Security Benefits

Pocan Introduces Food Worker Pay Standards Act

Baldwin, Braun, Schakowsky, Rooney Introduce Reform Requiring Transparency in Prescription Drug Price Increases

The bipartisan FAIR Drug Pricing Act takes the first step to address skyrocketing prescription drug costs

U.S. Senator Tammy Baldwin Helps Introduce Public Option for Affordable Care Act

As Trump Administration Renews Push for Total Affordable Care Act Repeal, Baldwin Supports Expanding Access to Quality Health Care

As Health Care Debate Shifts, Senator Baldwin and Senate Colleagues Lead Milestone Effort to Bring Down Prescription Drug Prices

Landmark proposal introduced by group of key Senate Democrats to improve the Affordable Care Act by addressing skyrocketing drug prices

Senators Have New Questions for Mylan About EpiPen Price Hike, Pricing Strategy

Company's previous response left unanswered questions about EpiPen pricing impact on consumers, taxpayers, and insurance premiums